In 2009, non-pathogenic variants in MMR genes were shown to be associated with neurofibroma load, possibly explaining variability in the number of neurofibromas and indicating a role of a biomarker to identify patients at risk for a high neurofibroma load (Fig. 1) [40]. This evidence concerns the gene MRC1 and neurofibroma.